Bambusa Therapeutics Inc.
BBTXHealthcare|Biotechnology|US
$15.73
-0.12 (-0.76%)
About
Bambusa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation diseases. The company was founded by Shan Shan Xu, Thang Ho, and Helmut Jeggle on March 14, 2024 and is headquartered in Boston, MA.
Stock Price
+4.9%(1Y)
1M
+4.9%
3M
+4.9%
6M
+4.9%
YTD
+4.9%
1Y
+4.9%
3Y
+4.9%
5Y
+4.9%
Pipeline Summary
6 total trials6
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 6
Active Trials (6)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
NCT07717905Chronic Spontaneous Urticaria
Phase 1Phase 2Recruiting
Enrollment: 48 participants
A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)
NCT06944925Chronic Obstructive Pulmonary Disease
Phase 1Recruiting
Enrollment: 286 participants
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
NCT06808477Atopic Dermatitis
Phase 1Recruiting
Enrollment: 237 participants
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
NCT07239947Atopic Dermatitis
Phase 1Recruiting
Enrollment: 99 participants
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With or Without Comorbid Asthma
NCT07436949Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Phase 1Phase 2Recruiting
Enrollment: 64 participants
Key Facts
Market Cap$782.8M
Employees26
CEOShan Shan Xu
IPO DateOct 30, 2026
Beta0.00
52-Week Range$13.6 – $17.42
Avg Volume633,842
ExchangeNASDAQ
Websitebambusatx.com
Ownership
Float6.2%
Shares Outstanding49.8M
Recent News
U.S. IPO Weekly Recap: Anthropic Files For Potentially Record-Breaking IPO
Oct 31, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 03:58 AM